Market closed
Achieve Life Sciences/$ACHV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Achieve Life Sciences
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
Ticker
$ACHV
Sector
Trading on
Industry
Biotechnology
Headquarters
Vancouver, Canada
Employees
25
Website
ACHV Metrics
BasicAdvanced
$92M
-
-$1.24
1.68
-
Price and volume
Market cap
$92M
Beta
1.68
52-week high
$5.59
52-week low
$2.65
Average daily volume
204K
Financial strength
Current ratio
5.457
Quick ratio
5.142
Long term debt to equity
47.385
Total debt to equity
47.648
Interest coverage (TTM)
-17.92%
Management effectiveness
Return on assets (TTM)
-84.19%
Return on equity (TTM)
-409.51%
Valuation
Price to book
4.4
Price to tangible book (TTM)
4.87
Price to free cash flow (TTM)
-2.855
Growth
Earnings per share change (TTM)
-17.42%
3-year earnings per share growth (CAGR)
-32.75%
What the Analysts think about ACHV
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Achieve Life Sciences stock.
ACHV Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ACHV Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ACHV News
AllArticlesVideos
Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 days ago
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
GlobeNewsWire·3 days ago
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
GlobeNewsWire·7 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Achieve Life Sciences stock?
Achieve Life Sciences (ACHV) has a market cap of $92M as of March 14, 2025.
What is the P/E ratio for Achieve Life Sciences stock?
The price to earnings (P/E) ratio for Achieve Life Sciences (ACHV) stock is 0 as of March 14, 2025.
Does Achieve Life Sciences stock pay dividends?
No, Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next Achieve Life Sciences dividend payment date?
Achieve Life Sciences (ACHV) stock does not pay dividends to its shareholders.
What is the beta indicator for Achieve Life Sciences?
Achieve Life Sciences (ACHV) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.